The CE approval for Supralimus?? and Supralimus-Core?? brings the company the distinction of being the first in the world to have CE approval for both Sirolimus and Paclitaxel -eluting coronary stents and in total three CE approved drug eluting stents.??
??
"The CE mark for Supralimus?? and Supralimus-Core?? is a significant accomplishment that substantiates our product's excellent clinical outcomes. This further confirms our commitment to providing patients and clinicians new treatment options for coronary artery disease." shared Dhirajlal Kotadia-CEO of Sahajanand, "The excellent flexibility, highly deliverable system and proven safety and efficacy of Sirolimus with the biodegradable polymers make our stents an excellent choice for a variety of patients" he added.
‘The drug coating in multiple layers with the use of biodegradable layers for the Supralimus and Supralimus Core stent is designed to deliver the drug in a biphasic manner: an initial burst dose, followed by a controlled release of the drug which will likely reduce late adverse clinical events compared to stents with non-biodegradable polymer' said Dr. Atul Abhyankar, Medical Director of SMT and a renowned cardiologist. "In the early days of evolution of drug eluting stents SMT had the
No comments:
Post a Comment